Selank – Nootropic Peptide

Selank is a synthetic heptapeptide with the amino-acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It is structurally related to the naturally occurring immunomodulatory peptide tuftsin and has been investigated primarily in neuropharmacology, anxiety-related behavioral models, GABAergic signaling, and peptide-mediated regulation of neurotransmission.

Selank is scientifically interesting because research has identified several potentially interacting biological mechanisms rather than a single definitively established molecular target. Experimental work has investigated its effects on GABA receptor systems, enkephalin-degrading enzymes, gene expression associated with neurotransmission, and selected neurobehavioral endpoints. Some studies have also examined changes in inflammatory or cytokine-related signaling.

The available evidence spans in-vitro experiments, animal/preclinical research, and a limited body of human clinical research, particularly from Russian-language clinical literature. These evidence categories should not be treated as interchangeable. Findings from receptor assays or animal models cannot by themselves establish human efficacy or safety.

Selank should therefore be regarded as a research compound rather than a universally established therapeutic product. Current regulatory information also underscores unresolved questions concerning human safety, including possible immunogenicity and peptide-related impurities for certain compounded preparations.

Chemical Information

Selank is a short synthetic peptide consisting of seven amino-acid residues:

Thr-Lys-Pro-Arg-Pro-Gly-Pro

The PubChem record identifies Selank as:

• Chemical name: L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolyl-glycyl-L-proline
• Peptide sequence: TKPRPGP
• Molecular formula: C33H57N11O9
• Molecular weight: 751.9 g/mol
• CAS Registry Number: 129954-34-3
• PubChem CID: 11765600
• InChIKey: JTDTXGMXNXBGBZ-YVHUGQOKSA-N
• Chemical class: synthetic oligopeptide/heptapeptide

These identifiers refer to the parent Selank molecule. Different salt forms should not automatically be treated as chemically identical for purposes of molecular weight, formulation, analytical characterization, or specification. For example, PubChem separately identifies Selank acetate and Selank diacetate.

Structurally, Selank contains seven amino-acid residues and several proline residues, giving it characteristics distinct from conventional small-molecule anxiolytics. Its peptide structure is also important when considering stability, enzymatic degradation, analytical characterization, and potential immunogenicity.

The PubChem molecular descriptors include a calculated molecular weight of 751.9 g/mol and a calculated topological polar surface area of 322 Ų. These are chemical descriptors and should not be interpreted as measurements of biological activity, membrane permeability, or human pharmacokinetics.

Mechanism of Action

GABAergic Signaling

One of the principal research areas surrounding Selank is the gamma-aminobutyric acid (GABA) receptor system, particularly GABA_A receptors.

A radioligand-receptor study reported that Selank altered [3H]GABA binding and characterized the peptide as a positive allosteric modulator of GABA receptor-related binding under the experimental conditions used. The authors proposed concentration-dependent modulation involving GABA receptor subtypes rather than describing Selank as a conventional direct GABA agonist.

This distinction is important. A positive allosteric modulator does not necessarily act in the same way as an orthosteric agonist. Allosteric modulation involves interaction with a regulatory site or state of a receptor and can alter the receptor’s response to its endogenous ligand.

Additional animal research examined gene expression associated with GABAergic neurotransmission following Selank administration. In rats, administration of Selank produced changes in the expression of numerous genes involved in neurotransmission, including genes related to GABA receptors, transporters, ion channels, and other neurotransmitter systems. The researchers reported similarities between some Selank-associated expression changes and those observed following GABA administration.

These findings support continued investigation of GABAergic mechanisms but do not establish that Selank produces a benzodiazepine-equivalent pharmacological effect in humans.

Enkephalin-Related Mechanisms

Another proposed mechanism concerns enkephalin metabolism.

In-vitro research found that Selank inhibited enzymes involved in the degradation of enkephalins. One study reported concentration-dependent inhibition of plasma enkephalin hydrolysis, while another study using human serum enzymes also observed inhibitory activity. These findings have been proposed as one possible contributor to the biological effects attributed to Selank.

The enkephalin-related mechanism is particularly relevant because enkephalins are endogenous opioid peptides involved in several physiological processes. However, inhibition of peptide-degrading enzymes in an experimental assay does not by itself demonstrate a clinically meaningful opioid effect, analgesic effect, or therapeutic benefit in humans.

Functional Signaling and Neurotransmission

Research has also examined Selank at the systems-neuroscience level. A functional-connectivity study involving healthy human participants investigated changes in resting-state brain connectivity after administration of Selank, with particular attention to the amygdala and prefrontal cortical regions. The study reported differences in functional connectivity involving the right amygdala and temporal cortical regions.

Such findings are useful for generating hypotheses concerning CNS activity, but functional neuroimaging changes should not automatically be interpreted as evidence of clinical efficacy.

Pharmacological Effects

In-Vitro Findings

In-vitro studies have investigated Selank’s interaction with GABA-related receptor systems and its inhibition of enzymes involved in enkephalin degradation.

The reported findings include:

• Modulation of [3H]GABA binding.
• Experimental evidence consistent with positive allosteric modulation of GABA receptor-related systems.
• Concentration-dependent inhibition of enkephalin-degrading enzymes.
• Biological activity of selected Selank peptide fragments in enzyme assays.

These experiments provide mechanistic information but do not establish therapeutic effectiveness in humans.

Animal and Preclinical Findings

Animal research has reported changes in anxiety-related and exploratory behavior, neurotransmitter-associated gene expression, memory-related experimental endpoints, and receptor-binding characteristics.

For example, experiments in BALB/c mice reported anxiolytic- and nootropic-associated behavioral effects under particular experimental conditions. The same study found that the observed effects differed according to administration route and mouse strain, illustrating the importance of experimental context.

Other animal studies have investigated Selank in models involving chronic stress, anxiety-like behavior, depression-related behavioral phenotypes, and experimentally induced memory impairment. These findings provide research hypotheses but should not be extrapolated directly to human clinical outcomes.

Human Evidence

Human evidence exists, but it is limited and should be interpreted cautiously.

A 2008 randomized clinical study reported on 62 patients with generalized anxiety disorder and neurasthenia, comparing Selank with medazepam. The authors reported anxiolytic effects in both groups and described additional effects associated with Selank.

A separate 2014 clinical study compared Selank with phenazepam in 60 patients with anxiety-related disorders and reported anxiolytic and mild nootropic effects.

These studies are evidence that Selank has been investigated in human participants; they should not, however, be interpreted as equivalent to the extensive modern clinical-development evidence required for a broadly established medicine. Important questions remain regarding independent replication, contemporary trial methodology, long-term safety, pharmacokinetics, manufacturing quality, and applicability to populations outside the studied settings.

Preclinical Research

Selank has been studied using several experimental systems.

Rodent Models

Research has included rats and mice, including:

• BALB/c mice in anxiety- and exploration-related behavioral experiments.
• C57BL/6 mice for comparison of strain-dependent responses.
• Rats exposed to chronic mild stress paradigms.
• Rat models involving experimentally induced memory impairment.
• Rodent brain-tissue studies examining receptor binding and neurotransmission-related gene expression.

The route of administration has varied between studies, including intranasal and intraperitoneal administration. Importantly, experimental effects have sometimes differed according to route and animal strain.

Experimental Dosing

Published preclinical studies have used experimental doses that should be interpreted only within their original research context.

For example, one mouse study administered 300 μg/kg/day for five days by intranasal or intraperitoneal routes and compared effects between BALB/c and C57BL/6 mice. Another rat study reported 0.5 mg/kg intraperitoneally in a specific experimental model of pharmacologically induced memory impairment.

These quantities are animal-study parameters, not recommended human doses. Differences in species, metabolism, administration route, formulation, peptide stability, experimental endpoint, and exposure make direct conversion to humans scientifically inappropriate.

No validated general human research dosage should be inferred from these animal experiments.

Dosage / Experimental Dosing

Selank has been administered experimentally in both animal and human research, but dosing should not be presented as a consumer-use recommendation.

Documented examples include:

Experimental context	Species	Route	Reported parameter
Anxiety/nootropic behavioral study	BALB/c and C57BL/6 mice	Intranasal or intraperitoneal	300 μg/kg/day for 5 days
Memory-related experimental model	Rats	Intraperitoneal	0.5 mg/kg
Human clinical research	Human participants	Reported in clinical literature	Study-specific clinical protocols

The animal values above are taken from specific published experiments and cannot be converted into a recommended human dose.

No universally validated human dosage has been established for research-grade Selank.

For laboratory work, investigators should use the protocol and exposure parameters specified in the relevant validated study rather than extrapolating from unrelated animal experiments.

Pharmacokinetics

Available research indicates that Selank undergoes enzymatic biodegradation.

A study using labeled Selank investigated its degradation in blood plasma and reported peptide fragments including TKPRP, TKP, RP, and GP as major products of biodegradation. The same research program investigated the distribution of labeled Selank following intranasal administration in experimental animals.

However, the publicly available evidence does not provide a sufficiently comprehensive human pharmacokinetic profile to establish reliable values for:

• Human terminal half-life.
• Human systemic bioavailability.
• Human dose-proportional exposure.
• Complete absorption characteristics.
• Quantitative tissue distribution.
• Definitive human blood-brain barrier penetration.
• Complete metabolic pathway.
• Human elimination kinetics.

Consequently, specific claims such as a fixed human half-life, precise onset, predictable duration, or quantified bioavailability should not be made without a source directly establishing the relevant parameter.

Side Effects and Safety

Safety assessment requires particular caution with research peptides.

Some published clinical and experimental reports describe Selank as well tolerated under their particular study conditions. However, the existence of such reports does not establish that commercially supplied research-grade material is safe for human administration.

Current FDA information specifically identifies Selank acetate (TP-7) among substances for which compounded preparations may pose risks related to immunogenicity under certain routes of administration, including concerns involving aggregation and peptide-related impurities. The FDA also states that it lacks important information concerning human safety for Selank acetate.

Potential safety considerations therefore include:

• Unknown effects associated with long-term exposure.
• Potential immunogenicity.
• Peptide aggregation.
• Impurities or incorrect peptide identity in inadequately characterized material.
• Route-specific risks.
• Unknown interactions with other pharmacologically active compounds.
• Uncertainty regarding effects in individuals with underlying medical conditions.

A laboratory product’s certificate of analysis can provide information about identity and purity but does not establish clinical safety.

Dependence, Tolerance and Withdrawal

Selank has been discussed in the literature in comparison with conventional anxiolytic agents, and experimental work has explored its interaction with GABAergic systems.

However, the available evidence does not justify describing Selank as non-addictive, dependence-free, or incapable of producing tolerance or withdrawal.

Conversely, the available evidence also does not establish a conventional benzodiazepine-like dependence syndrome for Selank. Claims in either direction should therefore be avoided unless supported by appropriate controlled evidence.

Any description of dependence potential should distinguish between demonstrated human findings, animal observations, receptor-level hypotheses, and absence of evidence.

Harm Reduction and Laboratory Safety

Selank should be handled as an experimental bioactive peptide.

Appropriate laboratory precautions include:

• Use accurate analytical measurement and appropriate validated methods for identity and purity.
• Maintain clear labeling of compound identity, concentration, batch information, and storage conditions.
• Follow the manufacturer’s validated storage requirements where available.
• Use appropriate laboratory PPE and contamination-control procedures.
• Avoid unnecessary exposure to the material.
• Store securely and restrict access to authorized personnel.
• Keep research compounds away from children and animals.
• Do not combine Selank with other pharmacologically active compounds without an appropriate scientific or medical rationale.
• Do not assume that proposed or experimentally observed changes in GABAergic activity eliminate risks associated with other CNS-active substances.
• Dispose of unused material according to applicable chemical and laboratory-waste procedures.

These precautions are particularly relevant because the biological consequences of experimental peptide exposure can depend on purity, formulation, route, concentration, and individual characteristics.

Legal and Regulatory Status

Regulatory status depends on jurisdiction, formulation, intended use, and whether a particular preparation is being marketed as a medicine, research material, compounded product, or another category.

The U.S. FDA currently maintains a specific entry for Selank acetate in its discussion of bulk substances that may present significant safety risks when used in compounding, citing concerns about immunogenicity and peptide-related impurities.

The FDA’s substance database separately identifies Selank as a validated peptide substance record, but registration or identification of a substance in a database should not be interpreted as marketing authorization.

For European jurisdictions, medicine authorization is jurisdiction-specific. The European Medicines Agency explains that its centralized database does not encompass every nationally authorized medicine, so absence from an EMA medicine page should not by itself be interpreted as a universal legal-status determination.

Users and businesses should therefore verify current requirements with the competent regulatory authority in the relevant country before importing, possessing, supplying, or using Selank.

Research Applications

Selank can be relevant to several areas of experimental research.

Receptor Pharmacology

Its reported effects on GABA receptor-associated binding make Selank a potential research tool for investigating peptide modulation of inhibitory neurotransmission.

Enkephalin and Peptidase Research

Because Selank has demonstrated inhibitory activity against selected enkephalin-degrading enzymes in experimental systems, it has been investigated in studies of endogenous peptide metabolism.

Neurotransmission Research

Gene-expression studies have examined the effects of Selank on genes involved in GABAergic and broader neurotransmitter systems.

Behavioral Neuroscience

Animal studies have investigated Selank in experimental models of anxiety-like behavior, stress, memory, and other neurobehavioral endpoints.

Structure-Activity and Peptide Research

The short sequence and defined molecular structure make Selank relevant to studies of peptide stability, enzymatic degradation, sequence-function relationships, and the biological properties of short regulatory peptides.

Conclusion

Selank is a synthetic seven-residue peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It has been investigated extensively in Russian and international scientific literature as an experimental neuroactive peptide.

The principal mechanistic research has focused on modulation of GABA receptor-associated signaling and inhibition of selected enkephalin-degrading enzymes. Animal studies have reported changes in anxiety-related behavior, neurotransmission-associated gene expression, receptor binding, and other experimental endpoints. Human clinical studies have also been published, including investigations involving anxiety disorders, but the overall evidence base remains substantially narrower than that supporting extensively characterized modern medicines.

Important uncertainties remain regarding comprehensive human pharmacokinetics, long-term safety, immunogenicity, formulation-dependent risks, and the reproducibility and generalizability of older clinical findings.

For these reasons, Selank should be presented accurately as an experimental research peptide rather than as an established treatment or a product with guaranteed therapeutic effects.

Research Use Only: Selank is intended for legitimate laboratory and scientific research where permitted by applicable law. It is not presented here as a medicine, dietary supplement, or recommendation for human or veterinary administration. No human dosage, therapeutic efficacy, long-term safety profile, or comprehensive pharmacokinetic profile should be inferred from preclinical studies.